English
SpanishTrusted Resources: Evidence & Education
Scientific literature and patient education texts
Effect of Long-Term Continuous Methimazole Treatment of Hyperthyroidism: Comparison With Radioiodine
source: European Journal of Endocrinology / European Federation of Endocrine Societies
year: 2005
authors: Azizi F, Ataie L, Hedayati M, Mehrabi Y, Sheikholeslami F
summary/abstract:Objective:
To investigate the long-term effects of continuous methimazole (MMI) therapy.
Design and Methods:
Five hundred and four patients over 40 years of age with diffuse toxic goiter were treated with MMI for 18 months. Within one year after discontinuation of MMI, hyperthyroidism recurred in 104 patients. They were randomized into 2 groups for continuous antithyroid and radioiodine treatment. Numbers of occurrences of thyroid dysfunction and total costs of management were assessed during 10 years of follow-up. At the end of the study, 26 patients were still on continuous MMI (group 1), and of 41 radioiodine-treated patients (group 2), 16 were euthyroid and 25 became hypothyroid. Serum thyroid and lipid profiles, bone mineral density, and echocardiography data were obtained.
Results:
There was no significant difference in age, sex, duration of symptoms and thyroid function between the two groups. No serious complications occurred in any of the patients. The cost of treatment was lower in group 1 than in group 2. At the end of 10 years, goiter rate was greater and antithyroperoxidase antibody concentration was higher in group 1 than in group 2. Serum cholesterol and low density lipoprotein-cholesterol concentrations were increased in group 2 as compared with group 1; relative risks were 1.8 (1.12-2.95, P<0.02) and 1.6 (1.09-2.34, P<0.02) respectively. Bone mineral density and echocardiographic measurements were not different between the two groups.
Conclusion:
Long-term continuous treatment of hyperthyroidism with MMI is safe. The complications and the expense of the treatment do not exceed those of radioactive iodine therapy.
DOI: 10.1530/eje.1.01904
read more full text
myBinderRelated Content
-
Risk Factors of Hepatic Dysfunction in Patients With Graves’ Hyperthyroidism and the Efficacy of 131iodine Tre...Hepatic dysfunction is often observed in...
-
Radioiodine Therapy Versus Antithyroid Medications for Graves’ DiseaseBackground: Graves' disease is the most...
-
How Vanessa Vanderstraaten Copes With the Disease, HyperthyroidismOn the surface, everything appears to be...
-
Hyperthyroidsm (Pediatric)Hyperthyroidism (overactive thyroid) is ...
-
Treatment Choice, Satisfaction and Quality of Life in Patients With Graves’ DiseaseBackground: Thyrotoxicosis, most often ...
-
Hyperthyroid Patients Without Graves’ Orbitopathy are not at Increased Risk of Developing Glaucoma: A Nationwi...Purpose: Graves' disease (GD) and toxic...
-
Radioiodine Ablation of Postsurgical Thyroid Remnants After Treatment With Recombinant Human TSH (rhTSH) in Patients...Context: Recent evidence suggests thyro...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Brought to you by
Supported through an independent
educational grant by
